// App-Quantinova.ai

TPS4595 : A phaseIII randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Neeraj Agarwal

  • Sumanta K. Pal

  • Maria Nirvana Formiga

  • Jun Guo

  • Daniel J. George

  • Mary Ann Tagliaferri

  • Alison L. Hannah

  • Jenny Yanzhen Zhang

  • Bridget A. O'Keeffe

  • Daniel C. Cho

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • City of Hope National Medical Center, Duarte, CA

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Duke University Cancer Institute, Durham, NC

  • Nektar Therapeutics, San Francisco, CA

  • Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

Locations

  • United States

  • China

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

  • Nivolumab

  • Sunitinib

  • NKTR214

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03729245

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved